Olivesi A
Gastroenterol Clin Biol. 1985 Aug-Sep;9(8-9):564-71.
In order to determine whether oral prednisolone efficiency in inflammatory bowel disease may be limited by impaired absorption, seven patients were studied. These were children with active disease, localized or extensive on the small and/or the large bowel. Serum prednisolone concentrations were compared within each subject after oral and intravenous administration of the same dose. Absorption was found complete, and its rate similar to that in nine normal adults. Thus prednisolone malabsorption did not limit treatment efficiency. In one patient, an alternative explanation was poor compliance with the treatment. Less complete studies in nine other children with active inflammatory bowel disease suggested the same conclusion. Prednisolone malabsorption in children with inflammatory bowel disease, if it exists, could only be transitory or exceptional.
为了确定口服泼尼松龙治疗炎性肠病的疗效是否会因吸收受损而受限,对7名患者进行了研究。这些患者均为患有活动性疾病的儿童,病变局限或广泛累及小肠和/或大肠。在同一剂量的泼尼松龙经口服和静脉给药后,比较了每个受试者体内的血清泼尼松龙浓度。结果发现吸收是完全的,其速率与9名正常成年人相似。因此,泼尼松龙吸收不良并未限制治疗效果。在1例患者中,另一种解释是对治疗的依从性差。对另外9例患有活动性炎性肠病的儿童进行的不太完整的研究也得出了相同的结论。炎性肠病患儿中若存在泼尼松龙吸收不良,也只会是暂时的或罕见的。